A growing body of preclinical and clinical trials has suggested that SGLT2 inhibitors could potentially enhance the condition of Non-Alcoholic Fatty Liver Disease (NAFLD) [54,55]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.